A new preprint study published on the preprint server medRxiv estimates how many lives were directly saved by vaccinating adults against COVID-19 in Europe from December 2020 through March 2023. Overall, the authors said the vaccines reduced deaths by 57% and saved an estimated 1.4 million lives in Europe.

As of March 2023, the 34 countries and territories in the World Health Organization’s European region had reported 2.2 million cases. The authors of the study estimated the impact of COVID-19 vaccination in adults by age-group, vaccine dose, and period of circulation of variants of concern.

Among adults over 25 years, 1.5 million lives (range, 0.7 to 2.6 million) were saved because of vaccines during the first 2.5 years of use. Overall, the first booster dose of vaccine delivered before the Omicron variant became dominant saved the most lives, 721,122 of 1,408,967 (57%) of all lives saved. The first booster dose became available in Europe in July 2021.

67% of lives saved during Omicron period

Most lives (67%) were saved during the Omicron period (942,571), and lives saved were almost all among adults ages 60 and older (96%, or 1,349,617).

Booster doses in older age-groups played an important role in saving lives.

The researchers previously estimated that vaccination directly saved 469,186 lives among people 60 years and older in 33 European countries during first year of the vaccination program.

"Booster doses in older age-groups played an important role in saving lives: early introduction of the first booster dose, which was recommended because of concerns about waning protection against severe disease," the authors said. "The first booster dose was responsible for the majority of lives saved, highlighting the importance of up-to-date vaccination in this high-risk age group."

A study of six US cities found a high prevalence of bacterial sexually transmitted infections (STIs) in transgender women (TGW), particularly those with HIV, researchers reported today in the Journal of Infectious Diseases.

Using baseline data from the Leading Innovation for Transgender Women's Health and Empowerment study, which examined HIV incidence and other health outcomes in TGW in six southeastern and eastern US cities (Atlanta, Baltimore, Boston, Miami, New York, and Washington, DC), a team led by researchers from Johns Hopkins Bloomberg School of Public Health analyzed bacterial STI test results from 1,018 participants. The primary outcome was the prevalence of at least one bacterial STI (gonorrhea, chlamydia, or syphilis) at any anatomic site.

Prevalence higher in those with HIV

The median age of participants was 29 years, 29% were Black, 27% were Hispanic, and 27% had HIV. The overall prevalence of any bacterial STI was 16% but was threefold higher in TGW with HIV (32% vs 11% among those without HIV). After adjustments for age, race and ethnicity, and region, HIV infection remained significantly associated with any bacterial STI (adjusted prevalence ratio, 1.9; 95% confidence interval, 1.39 to 2.62).

Among TGW without HIV, bacterial STI prevalence differed by geographic region, race and ethnicity, and gender identity, and was positively associated with reporting more than 1 sexual partner, hazardous alcohol use, homelessness, having safety concerns regarding transit to healthcare, and no prior receipt of gender-affirming health services. Among TGW with HIV, older age was inversely associated with bacterial STI.

...the variation in bacterial STI prevalence and correlates seen between TGW with and without HIV highlights the differential burden and needs of these two populations

The study authors say the findings underscore the need to develop interventions that are tailored to the unique needs and risks of each population.

"Although participants with and without HIV had a high prevalence of bacterial STIs, the variation in bacterial STI prevalence and correlates seen between TGW with and without HIV highlights the differential burden and needs of these two populations," they wrote. "Elucidating the ways in which situated vulnerabilities are associated with STI risk may help inform more tailored intervention strategies for each population."

A new large study published in CMAJ (Canadian Medical Association Journal) shows that even though the first 2 years of the pandemic resulted in significant disruptions to regular healthcare, preventable diseases and deaths didn't increase among Canadian children.

The study was based on emergency visits, hospital admissions, and deaths for children ages 0 to 17 years recorded in Ontario from January 2017 to February 2020 (the prepandemic period), with trends seen from March 2020 to August 2022.

All acute care and emergency visits dropped at the start of the pandemic, with the lowest number seen in April 2020. Compared to the prepandemic period, the adjusted relative rate (RR) for emergency visits was 0.28 (95% confidence interval [CI], 0.28 to 0.29), and hospital admissions was 0.43 (95% CI, 0.40 to 0.44). These decreases were sustained until September 2021 and May 2022, respectively, the authors said.

The only acute condition with significant delays in diagnosis in the first year of the pandemic was diabetes. Diabetes diagnoses dropped sharply in March, April, and May 2020, but rebounded in 2021 and 2022 (peak adjusted RR, 1.49; 95% CI, 1.28 to 1.74). Children diagnosed as having diabetes in 2021 and 2022 were more likely to present with diabetic ketoacidosis.

"While ongoing pandemic-related challenges, such as surgical wait times, for pediatric care persist, our analyses suggest that most urgent medical care needs of children were met despite the disruptions to the health care system," senior author Astrid Guttmann, MD, at the Hospital for Sick Children in Toronto, said in a press release.

Mpox cases continue to be reported at a low level in the European region, with 138 cases from 11 countries and areas reported over the last month, according to a joint update from the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) European regional office.

The groups are now posting the updates quarterly rather than monthly, noting that since their last report in October, the region has reported 472 cases from 19 cases and areas.

Countries reporting the most cases are still Spain, Portugal, the United Kingdom, and Germany.

Of mpox samples that were sequenced, all belonged to clade 2, known as the West African clade. Clade 2 is fueling the global outbreak in countries outside of Africa, which mainly involves men who have sex with men. Meanwhile, clade 1—known to be more virulent and deadly—is still spreading in Africa, where the virus was recently linked to a large outbreak in the Democratic Republic of Congo (DRC), the country's first involving sexual transmission of the virus.

• The Philadelphia Department of Public Health yesterday reported another confirmed measles case in the city's outbreak, raising the total to nine. The latest illness involves a fifth case related to exposures at a daycare facility. The outbreak began in December, with illnesses reported at a hospital, then a cluster in children at a daycare. The cluster at the daycare occurred after a sick patient attended the facility despite quarantine and exclusion instructions. City health officials are tracking potential exposures and are offering measles, mumps, and rubella (MMR) vaccination at multiple community sites.
• The US Senate Health, Education, Labor, and Pensions (HELP) committee announced yesterday that it will hold a full committee hearing at 9:00 am (EST) tomorrow on addressing long COVID, focusing on advancing research and improving patient care. In a statement, Sen. Bernie Sanders, (I.-Vt.) said that the impact of the pandemic is still felt by millions of families. "Lives are at stake. I look forward to hearing from patients, experts, and researchers about what we must do to address this crisis, including the advanced research and patient care that so many Americans desperately need," he said. The committee will hear testimony from two panels, one a group of long-COVID patients and the other comprising medical doctors and researchers.
• Brazil's health ministry this week announced some initial details about a plan to launch the dengue vaccine through its public system, which will make it the first country in the world to do so. The ministry incorporated the Qdenga vaccine, made by Takeda, in December and said the company expects to deliver 5.2 million doses between February and November. The company has donated another 12 million doses. Officials said doses will be staggered throughout the year, based on the company's vaccine delivery schedule, with a goal of vaccinating about 3.2 million people with the two-dose schedule. Technical experts advised the ministry that doses be prioritized to children ages 6 to 16 years old, based on World Health Organization recommendations. The Americas region reported record dengue cases in 2023, with Brazil as the hardest hit country.